Relay Therapeutics sells 22.9 million shares at $12.00 each in public offering
Relay Therapeutics agreed on May 20, 2026 to sell 22,916,667 shares of common stock at $12.00 per share in an underwritten public offering. The underwriters exercised in full their option to buy 3,437,500 additional shares on May 21, 2026, and the company estimates net proceeds of about $296.8 million, with closing expected on May 22, 2026. The sale adds shares outstanding, which affects existing shareholders' ownership, and the proceeds are the company's own estimate.
Key points
- Offering of 22,916,667 shares at $12.00 per share, under a May 20, 2026 Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC
- Underwriters exercised in full their 30-day option for an additional 3,437,500 shares on May 21, 2026
- Estimated net proceeds of approximately $296.8 million after underwriting discounts and offering expenses
- Expected closing on May 22, 2026, subject to customary conditions
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 21, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.